Overcoming challenges in co-formulation of proteins with contradicting stability profiles

Overcoming challenges in co-formulation of proteins with contradicting stability profiles - EPO plus G-CSF

Published:2020-01 Issue: Volume:141 Page:105073
ISSN:0928-0987
Container-title:European Journal of Pharmaceutical Sciences
language:en
Short-container-title:European Journal of Pharmaceutical Sciences

Author:

Krieg Dennis,Svilenov Hristo,Gitter Julian H.,Winter Gerhard

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference39 articles.

1. Challenges for the pharmaceutical technical development of protein coformulations;Mueller;J. Pharm. Pharmacol.,2018

2. Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer;Hamizi;Onco Targets Ther.,2013

3. Fernandes P.M., Taforo T. Formulations for lipophilic IL-2 proteins, U.S. Patent, No. 4992271. 1991.

4. Formulation and stability of cytokine therapeutics;Lipiäinen;J. Pharm. Sci.,2015

5. Development of a subcutaneous fixed-dose combination of pertuzumab and trastuzumab: results from the phase Ib dose-finding study;Kirschbrown;J. Clin. Pharmacol.,2018

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stability Convergence in Antibody Coformulations;Molecular Pharmaceutics;2022-10-20

2. Systematic Studies on Stabilization of AAV Vector Formulations by Lyophilization;Journal of Pharmaceutical Sciences;2022-08

3. It is Never Too Late for a Cocktail - Development and Analytical Characterization of Fixed-dose Antibody Combinations;Journal of Pharmaceutical Sciences;2022-08

4. Room Temperature Intrinsic Emission Ratio of BSA Correlates With Percent Aggregates During Long-Term Storage;Journal of Pharmaceutical Sciences;2021-03

5. Stability enhancement in a mAb and Fab coformulation;Scientific Reports;2020-12